The stock was sold at an average price of $17.81, for a total value of $209,997. The company has a one-year low of $1,309 and a one-year high of $1,847.
The company’s fourth quarter revenue was up 2 percent to $1.2 billion. The trading profit was up 7 percent to $325 million and the global advanced wound management business line was down 2 percent. Also, the full year, revenue was up 2 percent to $4.6 billion.
More articles on devices:
27 spine devices receive FDA 510(k) clearance in January
MiMedx withdraws complaint against Organogenesis
NuVasive COO sells 15k shares — 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
